ACGT Progenomics

Executive Summary

ACGT Progenomics is a privately held, US-based contract research organization (CRO) specializing in DNA sequencing and molecular biology services since 1993. The company offers Sanger sequencing, whole plasmid sequencing, and next-generation sequencing (NGS) for both research and regulatory applications. With a focus on quality, compliance, and expert customer support, ACGT has established itself as a reliable partner for academic, pharmaceutical, and clinical clients. While the company operates in the competitive genomics services market, its decades-long track record and niche in plasmid sequencing provide a stable foundation. However, as a private firm with no disclosed funding or valuation, its growth trajectory appears moderate, relying on organic expansion and client retention rather than aggressive scaling. The company's low public profile suggests a conservative approach, but its established reputation in the Midwest biotech ecosystem supports steady operations.

Upcoming Catalysts (preview)

• Q3 2026Expansion of NGS service menu to include long-read sequencing (e.g., PacBio or Oxford Nanopore)40% success
• TBDPartnership with a mid-size biopharma for clinical trial sample processing30% success